Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.57 |
| ▸ | CSNK2A2 | P19784 | 6/20 | 0.48 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 7/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | BCL6 | P41182 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30279917 | 1.00 | CDK2 (0.57) | CDK2CSNK2A2KDM4DCSNK2A1MAPKAPK2 | |
| SCHEMBL30279846 | 0.82 | KDM4E (0.54) | CDK2CSNK2A2KDM4DCSNK2A1KDM4E | |
| SCHEMBL19742544 | 0.80 | CDK2 (0.53) | CDK2CSNK2A2CSNK2A1MAPKAPK2BCL6 | |
| SCHEMBL30279929 | 0.80 | CDK2 (0.53) | CDK2CSNK2A2CSNK2A1MAPKAPK2BCL6 | |
| SCHEMBL19742583 | 0.79 | CSNK2A1 (0.59) | CDK2CSNK2A2KDM4DCSNK2A1MAPKAPK2 | |
| SCHEMBL33377988 | 0.79 | CDK2 (0.42) | CDK2MAPK1 | |
| SCHEMBL19742461 | 0.78 | CDK2 (0.51) | CDK2CSNK2A2CSNK2A1MAPKAPK2ALDH1A1 | |
| SCHEMBL30279953 | 0.78 | CDK2 (0.51) | CDK2CSNK2A2CSNK2A1MAPKAPK2ALDH1A1 | |
| SCHEMBL33378018 | 0.78 | CHEK1 (0.45) | CDK2CSNK2A2MAPKAPK2 | |
| SCHEMBL30083482 | 0.76 | CDK2 (0.63) | CDK2CSNK2A2CSNK2A1KDM4ECLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3474855-B1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3474855-B1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3474855-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Polaris Pharmaceuticals, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | POLARIS PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | POLARIS PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS | 2017-12-28 | — | — | US | disclosed |
| WO-2017223432-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | CSNK1A1, CSNK2A1, CSNK2A3 | CDK2 14/4885CSNK2A2 4/4885KDM4D 2975/4885 |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | CSNK1A1, CSNK2A1, CSNK2A3 | CDK2 14/4885CSNK2A2 4/4885KDM4D 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.